NCT04252066Recruiting
A Global Prospective Observational Study of Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding
Source: ClinicalTrials.gov · Last updated 28 Oct 2026
Brief summary (registry, in English)
This is a global prospective observational study of women with Fabry disease and their infants during pregnancy and/or breastfeeding. The study will evaluate outcomes of pregnancy and/or breastfeeding in women and infants exposed to migalastat.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 20 (estimated)
- First submitted
- 18 Dec 2019
- Start date
- 18 Mar 2025
- Primary completion date
- Aug 2029
- Lead sponsor
- Amicus Therapeutics
- Diseases
- Fabry disease
- NCT number
- NCT04252066
What you commit to
- Study type: Observational
- Planned participants: 20
- From 18 Mar 2025 to the primary completion date, Aug 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- None
Who the study is looking for
- Female patients meeting the following criteria will be eligible for study enrollment:
- Patients with Fabry disease who are pregnant and/or breastfeeding, whether or not they are exposed to migalastat
- Able and willing to provide informed consent or assent, if applicable.
- Able and willing to provide HCP contact information.
Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Amicus Therapeutics, Inc. Pregnancy Registry Coordinator of this site? Confirm its status | Philadelphia | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.